Status:
COMPLETED
Prevalence of Osteoporosis in Sickle Cell Disease
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Sickle Cell Disease
Eligibility:
All Genders
20-40 years
Brief Summary
Sickle cell disease is the most common single-gene disease in the world. Its prevalence is increasing in France, with patients' life expectancy increasing into developed countries. It mainly affects p...
Eligibility Criteria
Inclusion
- Black-skinned men and women
- Aged 20 to 40 years old
- Sickle cell patients
- Non-opposition to participate in the study
Exclusion
- Refusal to participate in the study
- Hemoglobinopathy other than sickle cell disease
- Severe or End Stage Renal Failure
- Long-term corticosteroid therapy (\>3 months)
- History of solid cancer or malignant haemopathy
- History of organ transplantation
- Pregnant or breastfeeding woman
- Psychiatric pathology seriously impeding understanding
- Difficulty understanding oral French
Key Trial Info
Start Date :
June 18 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 18 2021
Estimated Enrollment :
142 Patients enrolled
Trial Details
Trial ID
NCT04299594
Start Date
June 18 2020
End Date
December 18 2021
Last Update
February 9 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Edouard Herriot
Lyon, France, 69437